-
Mashup Score: 1
Keep up with live updates of the FDA Advisory Committee meeting on talazoparib plus enzalutamide for mCRPC.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
The first clinical trial site has been activated in the pivotal phase 3 AMPLIFY trial, evaluating the efficacy and safety of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer. #pcsm https://t.co/Wt975zErQA
-
-
Mashup Score: 3Remote Prostate HIFU Marks Global Surgery Milestone - 7 day(s) ago
Ruben Olivares, MD, discusses the first remote transcontental HIFU therapy for prostate cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
WATCH: Ruben Olivares, MD, discusses the first remote transcontental HIFU therapy for prostate cancer. #pcsm | @CleClinicMD @FocalOneHIFU https://t.co/MEKgL3uiJQ
-
-
Mashup Score: 0
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care. #pcsm | @DrScottTagawa https://t.co/BxSWJqdlsj
-
-
Mashup Score: 6Improving Health Equity: The First Transcontinental HIFU Procedure in Prostate Cancer - 12 day(s) ago
Ruben Olivares, MD, discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
WATCH: @RubenOlivaresG discusses the important implications of the first transcontinental robot-assisted focal therapy procedure for prostate cancer. #pcsm | @CleClinicUro @FocalOneHIFU https://t.co/mUGUGJPyhE
-
-
Mashup Score: 5FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium - 13 day(s) ago
Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Findings from ongoing clinical trials, such as the phase 3 PEACE III and the PSMAfore studies, have demonstrated an emergence of promising agents for patients with CRPC, including radium-223 and Pluvicto, respectively. @YungLyou @Providence #pcsm https://t.co/dmfhbcIk7q https://t.co/xnI6gvPc8X
-
-
Mashup Score: 1
Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Elraglusib in combination with GnP demonstrated a statistically significant improvement in OS vs GnP alone as a first-line treatment for patients with metastatic PDAC. #pcsm https://t.co/w9Z1ZnJPWT https://t.co/FgYNWhB5MG
-
-
Mashup Score: 3Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world - 16 day(s) ago
Investigators found that benefits of treatments that are observed in trials also appear in the real world.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Stephen J. Freedland, MD, (@SFreedlandMD) discusses the benefits of mCRPC treatments translating to the real-world. @CS_Urology #pcsm https://t.co/O57OhqF6nC
-
-
Mashup Score: 3Leveraging Beta and Alpha Emitters in Metastatic CRPC Management - 16 day(s) ago
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer. #pcsm | @DrScottTagawa @AmerUrological https://t.co/FjX8RzSKsQ
-
-
Mashup Score: 1
“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet-
Joy Maulik, CRNP, discusses the importance of genetic testing in prostate cancer. @ChesUrology #pcsm https://t.co/nEvWtYOJwG
-
The @US_FDA's Oncologic Drugs Advisory Committee is meeting today to discuss the submitted sNDA for talazoparib plus enzalutamide for patients with mCRPC unselected for HRR gene alterations. #pcsm Keep up with live updates from the meeting here: https://t.co/lnwXghxD5h